One of the most consistent findings in longevity research is that early detection changes outcomes. Most of the diseases that kill people prematurely - cardiovascular disease, cancer, diabetes, osteoporosis - are far more treatable in their early stages than after they have progressed to produce symptoms. By the time you feel sick, the disease has often been developing for years or decades.

Preventive screening is the systematic search for disease before symptoms appear. Done well, it is one of the highest-return investments in longevity available. Done poorly - with tests that lack evidence, produce false positives, or lead to unnecessary treatment - it can cause harm. The key is knowing which screenings have strong evidence and which do not.

Blood pressure screening is the highest-value preventive test available. It is inexpensive, non-invasive, and identifies one of the most powerful modifiable risk factors for cardiovascular disease, stroke, kidney disease, and dementia.

Hypertension affects roughly half of American adults and produces no symptoms until it has caused significant organ damage. The U.S. Preventive Services Task Force (USPSTF) recommends blood pressure screening for all adults 18 and older, with annual screening for adults 40 and older and those at increased risk.

Home blood pressure monitoring is more accurate than office measurements for most people and provides far more data. A validated home monitor costs $30-50 and is one of the most cost-effective health investments available.

Target: Below 120/80 mmHg. Stage 1 hypertension (130-139/80-89) warrants lifestyle intervention; Stage 2 (140/90 or higher) typically requires medication.

Cardiovascular disease is the leading cause of death in the United States, and lipid abnormalities are a primary driver. A fasting lipid panel measures total cholesterol, LDL (low-density lipoprotein), HDL (high-density lipoprotein), and triglycerides.

The USPSTF recommends lipid screening for men starting at 35 and women starting at 45, with earlier screening for those with cardiovascular risk factors. Many clinicians recommend starting at 20 and repeating every 5 years in low-risk individuals.

Beyond the standard lipid panel, several additional markers provide more complete cardiovascular risk assessment:

ApoB (apolipoprotein B) measures the number of atherogenic particles in the blood and is a more accurate predictor of cardiovascular risk than LDL cholesterol alone. Each LDL particle carries one ApoB molecule, so ApoB directly counts the particles that can penetrate arterial walls.

Lp(a) (lipoprotein(a)) is a genetically determined cardiovascular risk factor that is not captured by standard lipid panels. Elevated Lp(a) is present in approximately 20% of the population and significantly increases cardiovascular risk. It should be measured at least once in every adult.

hsCRP (high-sensitivity C-reactive protein) measures systemic inflammation and adds predictive value for cardiovascular risk beyond lipids alone.

Type 2 diabetes and prediabetes affect more than 130 million Americans, and approximately one-third of those with diabetes are undiagnosed. Diabetes dramatically accelerates aging through multiple mechanisms: it promotes inflammation, damages blood vessels, impairs immune function, and accelerates cognitive decline.

The USPSTF recommends screening for prediabetes and type 2 diabetes in adults aged 35-70 who are overweight or obese. Many clinicians recommend broader screening starting at 35 regardless of weight, given the high prevalence of metabolic dysfunction.

Fasting glucose and HbA1c (a measure of average blood glucose over the past 2-3 months) are the standard screening tests. Fasting insulin, which is not routinely ordered but is highly informative, can identify insulin resistance years before glucose levels rise - the earliest stage of metabolic dysfunction when intervention is most effective.

Colorectal cancer is the second leading cause of cancer death in the United States, and it is one of the most preventable cancers when caught early. The five-year survival rate for localized colorectal cancer is 90%; for metastatic disease, it is 14%.

The USPSTF recommends colorectal cancer screening starting at age 45 for average-risk adults. Multiple screening options exist:

Colonoscopy every 10 years is the gold standard. It allows direct visualization of the entire colon and removal of precancerous polyps during the same procedure. A colonoscopy that finds and removes polyps is not just screening - it is prevention.

Stool-based tests (FIT, Cologuard) are less invasive alternatives that can be done at home. They require more frequent testing (annually for FIT, every 1-3 years for Cologuard) and any positive result requires follow-up colonoscopy.

For people with a family history of colorectal cancer or polyps, screening should begin earlier and may need to be more frequent.

Breast cancer is the most common cancer in women (excluding skin cancers) and the second leading cause of cancer death in women. Mammography screening reduces breast cancer mortality by detecting tumors before they spread.

Screening recommendations have evolved and vary by organization. The American Cancer Society recommends annual mammography starting at 40 for average-risk women. The USPSTF recommends biennial mammography from 40-74. Women with higher risk (family history, BRCA mutations, dense breast tissue) may benefit from earlier and more frequent screening, and potentially MRI in addition to mammography.

Dense breast tissue - present in approximately 40% of women - reduces mammography sensitivity and independently increases breast cancer risk. Women should be informed of their breast density and discuss supplemental screening options with their physician.

Cervical cancer is almost entirely preventable through a combination of HPV vaccination and regular screening. The Pap smear (cytology) and HPV test detect precancerous changes before they progress to cancer.

Current USPSTF recommendations: Pap smear every 3 years for women 21-65, or Pap smear plus HPV co-testing every 5 years for women 30-65. Women who have had a total hysterectomy for non-cancerous reasons do not need cervical screening.

Lung cancer is the leading cause of cancer death in the United States, and it is typically diagnosed at an advanced stage when treatment options are limited. Low-dose CT (LDCT) screening can detect lung cancer at an early, treatable stage.

The USPSTF recommends annual LDCT screening for adults aged 50-80 who have a 20 pack-year smoking history and currently smoke or have quit within the past 15 years. This recommendation reflects the high risk in this population and the demonstrated mortality benefit of screening.

Osteoporosis affects approximately 10 million Americans and is a major cause of fracture, disability, and mortality in older adults. Bone density loss is silent - there are no symptoms until a fracture occurs.

The USPSTF recommends bone density screening (DEXA scan) for women 65 and older, and for younger postmenopausal women with risk factors. Men are screened less routinely, but men over 70 or those with risk factors (steroid use, low testosterone, family history) should discuss screening with their physician.

Skin cancer is the most common cancer in the United States, with over 5 million cases diagnosed annually. Melanoma, the most dangerous form, is highly curable when caught early and often fatal when caught late.

Annual full-body skin examination by a dermatologist is recommended for people with risk factors including fair skin, history of sunburns, family history of melanoma, or many moles. Monthly self-examination using the ABCDE criteria (Asymmetry, Border irregularity, Color variation, Diameter greater than 6mm, Evolution) can detect suspicious lesions between professional exams.

Abdominal aortic aneurysm (AAA) - a dangerous enlargement of the main abdominal artery - is largely asymptomatic until it ruptures, at which point mortality is 80%. The USPSTF recommends one-time ultrasound screening for men aged 65-75 who have ever smoked. This is a simple, inexpensive test that can identify aneurysms before they become life-threatening.

Preventive screening is not a substitute for healthy lifestyle habits - it is a complement to them. The goal is to catch the diseases that lifestyle cannot fully prevent, and to catch them early enough that treatment is effective.

The screenings listed here represent the strongest evidence base for mortality reduction. Not every test marketed as "preventive" has this evidence - many executive health panels include tests with limited proven benefit. Focusing on the evidence-based screenings, done at the recommended intervals, is the most efficient use of healthcare resources for longevity.

Work with a physician who takes prevention seriously, knows your family history, and can tailor screening recommendations to your individual risk profile. The conversation about what to screen for, and when, is one of the most valuable you can have for your long-term health.